B9D2

Across TCGA pan-cancer cohorts, B9D2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B9D2 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher B9D2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B9D2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where B9D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.342	1.000	.001	24	view →
PDAC	DFS	Median	All	0.190	0.486	.030	5	view →
LUAD	DFS	Quartile	All	0.804	1.000	.003	4	view →
CCRCC	OS	Quartile	All	1.000	0.784	.016	4	view →
LSCC	DFS	Median	All	0.606	0.795	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B9D2–UCEC (DFS)

Open the UCEC breakdown →